ApiChina
客服QQ:125879888
首页»供应»医药、保养 » 原料药»CAS 150915-40-5

CAS 150915-40-5

  • 面议
  • 起订量:0
  • 可售数量:0
  • 发布时间:2021-03-30产品供应时间:长期有效

所在地:浙江杭州市

企业类型:企业单位

公司地址:浙江省杭州市西湖区莲花峰路12号

联系人:沈 (先生)
手机:未填写
在线联系:
传真:未填写
立即询价
加入购物车
告诉好友
违规举报
分享拿好礼:
企业信息
  • 浙江凯发工贸有限公司
  • [免费会员1年] 信用度:0级
  • 会员级别:普通会员 第1年 信用度:0级
  • 店铺等级:
  • 联系人:沈(先生) 
  • 已缴纳 0.00 元保证金
  • 在线联系:
  • 会员状态:[当前离线] [加为商友] [发送信件]
  • 企业类型:企业单位
  • 经营模式:贸易商,服务商
  • 经营范围:原料药与中间体
  • 产品详情
  • 联系方式
  • 产品评价
  • 品牌:
  • 所属分类:医药、保养 » 原料药
  • 计量单位:
  • 最小起订量:0
  • 供货总量:0
  • 发货期限:自买家付款之日起3天内发货

 Product Name: Tirofiban hydrochloride monohydrate

Synonym: TIROFIBAN, HYDROCHLORIDE HYDRATE;Tirofiban HCl;TirofibanHcl142373-60-2/;N-(Butylsulfonyl)-O-[4-(4-piperidynyl)butyl]-L-tyrosine, Hydrochloride Hydrate;(2S)-2-(Butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid hydrochloride hydrate;N-(Butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine monohydrochloride monohydrate;Tirofiban hydrochloride monohydrate;Tirofiban hcl Monohydrate

MF: C22H39ClN2O6S

MW: 495.07

Product Category: Cardiovascular APIs;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API

Melting Point: 135-137°C

Storage Temp.: -20°C Freezer

Solubility: DMSO: >12mg/mL at warmed to 60°C

Form: powder

Color: white to beige

Optical Activity: [α]/D -10 to -18° (c=1, MeOH)

Merck: 14,9464

Hazard Codes: Xi

Risk Statements: 36/37/38

Safety Statements: 26-37-45

WGK Germany: 3

Tirofiban Hyderochloride Monohydrate: Tirofiban is an anti-angina drug, it is successfully developed by the United States Merck company , Patent Number is EP 478363, and in 1998 it was sold in the United States, the trade name is Aggrastat,it is clinically used in treating acute coronary syndromes, including unstable angina or non-Q-wave myocardial infarction, and percutaneous transluminal coronary angioplasty (PTCA) or atherosclerotic plaque excision patients with in combination with heparin. 

Drugs currently used in clinical are mainly tirofiban hydrochloride injections under the tradename Xin Weining, it is a reversible non-peptide platelet surface glycoprotein (GP) Ⅱb/Ⅲa receptor antagonist, it can competitively inhibit combination of fibrinogen and platelet (GP) Ⅱb/Ⅲa receptor . Intravenous injection is a dose-dependent inhibition of outside human platelet aggregation, prolonged bleeding time,and thrombosis caused by ADP, collagen, arachidonic acid,thromboxane analog U46619 and thrombin. 
In healthy volunteers ,they are injected in routinely recommended doses, the peak plasma concentration is similar to that of steady-state plasma concentrations during the infusion ,T1/2 is 2h. Within 0.01~25 μg/ml dose range, PPB of this product is 65%, independent of concentration. Free drug accounts for 35% in plasma, Vd is 22~42 L. In healthy volunteers, CL is 213~314 ml/min, the renal clearance rate is 39%-69% of plasma clearance. 
[Usage ]
(1) tirofiban hydrochloride monohydrate in combination with heparin is used in treating acute coronary syndromes, including unstable angina or non-Q-wave myocardial infarction, and percutaneous transluminal coronary angioplasty (PTCA) or atherectomy artery surgery patients. 
(2) to give this product 0.4μg/(kg · min) bolus, 300 min, followed by a maintenance dose of 0.1μg/(kg · min). Unstable angina or non-Q-wave myocardial infarction patients need an infusion of 48~108 h. Row PTCA or atherectomy arterial patients need to continue infusion 12~24 h after surgery.

Precaution: 1. Adverse reactions: The most common adverse reactions are fever, or bleeding complications; other visible adverse reactions are nausea, headache, rash or urticaria, systemic reactions visible is reduction in platelet count. 

2. Disable: allergy to the drug, the use of tirofiban in patients with thrombocytopenia occurring, there is active bleeding or bleeding constitution history before 30 days, history of intracranial hemorrhage, nearly a month of stroke or brain hemorrhage stroke, intracranial tumors, aneurysms, arteriovenous malformations, vital organs, surgery or severe trauma requiring surgical treatment, patients with aortic dissection, pericarditis, severe hypertension. 
3. caution: recent (1 year) bleeding in patients, with coagulopathy, platelet disorder, or a history of thrombocytopenia, platelet count less than 150 × 109/L patients who have a history of cerebrovascular disease (1 year) , with recent subdural extracapsular surgery, nearly a month having a major surgery or a history of severe physical trauma, dissecting aneurysm, hemorrhagic retinal diseases, chronic hemodialysis patients.

Uses: Acute coronary syndrome (angina pectoris, myocardial infarction, surgery hydrant). 

Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa inhibitor. It can prevent platelet aggregation and thrombosis.

Chemical Property: White Solid

Uses: A specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. An antithrombotic used in the treatment of unstable angina

Uses: Tirofiban is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Tirofiban is an antithrombotic used in the treatment of unstable angina.

关键词:CAS 150915-40-5,供应,医药、保养,原料药

  • 产品详情
  • 联系方式
  • 产品评价
立即询价 面议